These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 21812041)
1. New molecular markers for prostate tumor imaging: a study on 2-methylene substituted fatty acids as new AMACR inhibitors. Morgenroth A; Urusova EA; Dinger C; Al-Momani E; Kull T; Glatting G; Frauendorf H; Jahn O; Mottaghy FM; Reske SN; Zlatopolskiy BD Chemistry; 2011 Aug; 17(36):10144-50. PubMed ID: 21812041 [TBL] [Abstract][Full Text] [Related]
2. Branched fatty acids in dairy and beef products markedly enhance alpha-methylacyl-CoA racemase expression in prostate cancer cells in vitro. Mobley JA; Leav I; Zielie P; Wotkowitz C; Evans J; Lam YW; L'Esperance BS; Jiang Z; Ho SM Cancer Epidemiol Biomarkers Prev; 2003 Aug; 12(8):775-83. PubMed ID: 12917210 [TBL] [Abstract][Full Text] [Related]
3. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Luo J; Zha S; Gage WR; Dunn TA; Hicks JL; Bennett CJ; Ewing CM; Platz EA; Ferdinandusse S; Wanders RJ; Trent JM; Isaacs WB; De Marzo AM Cancer Res; 2002 Apr; 62(8):2220-6. PubMed ID: 11956072 [TBL] [Abstract][Full Text] [Related]
4. Alpha-methylacyl-CoA racemase as an androgen-independent growth modifier in prostate cancer. Zha S; Ferdinandusse S; Denis S; Wanders RJ; Ewing CM; Luo J; De Marzo AM; Isaacs WB Cancer Res; 2003 Nov; 63(21):7365-76. PubMed ID: 14612535 [TBL] [Abstract][Full Text] [Related]
5. Alpha-methylacyl-CoA racemase (P504S) expression in evolving carcinomas within benign prostatic hyperplasia and in cancers of the transition zone. Leav I; McNeal JE; Ho SM; Jiang Z Hum Pathol; 2003 Mar; 34(3):228-33. PubMed ID: 12673556 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of human α-methylacyl CoA racemase (AMACR): a target for prostate cancer. Carnell AJ; Kirk R; Smith M; McKenna S; Lian LY; Gibson R ChemMedChem; 2013 Oct; 8(10):1643-7. PubMed ID: 23929631 [TBL] [Abstract][Full Text] [Related]
7. Conversion of prostate cancer from hormone independency to dependency due to AMACR inhibition: involvement of increased AR expression and decreased IGF1 expression. Takahara K; Azuma H; Sakamoto T; Kiyama S; Inamoto T; Ibuki N; Nishida T; Nomi H; Ubai T; Segawa N; Katsuoka Y Anticancer Res; 2009 Jul; 29(7):2497-505. PubMed ID: 19596919 [TBL] [Abstract][Full Text] [Related]
8. Novel 2-arylthiopropanoyl-CoA inhibitors of α-methylacyl-CoA racemase 1A (AMACR; P504S) as potential anti-prostate cancer agents. Yevglevskis M; Nathubhai A; Wadda K; Lee GL; Al-Rawi S; Jiao T; Mitchell PJ; James TD; Threadgill MD; Woodman TJ; Lloyd MD Bioorg Chem; 2019 Nov; 92():103263. PubMed ID: 31536953 [TBL] [Abstract][Full Text] [Related]
10. Peroxisomal branched chain fatty acid beta-oxidation pathway is upregulated in prostate cancer. Zha S; Ferdinandusse S; Hicks JL; Denis S; Dunn TA; Wanders RJ; Luo J; De Marzo AM; Isaacs WB Prostate; 2005 Jun; 63(4):316-23. PubMed ID: 15599942 [TBL] [Abstract][Full Text] [Related]
11. A nonclassic CCAAT enhancer element binding protein binding site contributes to alpha-methylacyl-CoA racemase expression in prostate cancer. Zha S; Isaacs WB Mol Cancer Res; 2005 Feb; 3(2):110-8. PubMed ID: 15755877 [TBL] [Abstract][Full Text] [Related]
13. Kinetic fluorescence reverse transcriptase-polymerase chain reaction for alpha-methylacyl CoA racemase distinguishes prostate cancer from benign lesions. Schostak M; Miller K; Krause H; Schrader M; Kempkensteffen C; Kollermann J Cancer Detect Prev; 2006; 30(5):449-54. PubMed ID: 17067752 [TBL] [Abstract][Full Text] [Related]
14. Alpha-methylacyl-CoA racemase: a multi-institutional study of a new prostate cancer marker. Jiang Z; Wu CL; Woda BA; Iczkowski KA; Chu PG; Tretiakova MS; Young RH; Weiss LM; Blute RD; Brendler CB; Krausz T; Xu JC; Rock KL; Amin MB; Yang XJ Histopathology; 2004 Sep; 45(3):218-25. PubMed ID: 15330799 [TBL] [Abstract][Full Text] [Related]
15. Alpha-Methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions. Zhou M; Chinnaiyan AM; Kleer CG; Lucas PC; Rubin MA Am J Surg Pathol; 2002 Jul; 26(7):926-31. PubMed ID: 12131161 [TBL] [Abstract][Full Text] [Related]
16. A variant of the alpha-methyl-acyl-CoA racemase gene created by a deletion in exon 5 and its expression in prostate cancer. Mubiru JN; Valente AJ; Troyer DA Prostate; 2005 Oct; 65(2):117-23. PubMed ID: 15880524 [TBL] [Abstract][Full Text] [Related]
17. Alternative spliced variants of the alpha-methylacyl-CoA racemase gene and their expression in prostate cancer. Mubiru JN; Shen-Ong GL; Valente AJ; Troyer DA Gene; 2004 Feb; 327(1):89-98. PubMed ID: 14960364 [TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and in vitro testing of alpha-methylacyl-CoA racemase inhibitors. Carnell AJ; Hale I; Denis S; Wanders RJ; Isaacs WB; Wilson BA; Ferdinandusse S J Med Chem; 2007 May; 50(11):2700-7. PubMed ID: 17477519 [TBL] [Abstract][Full Text] [Related]
19. Sequence variants of alpha-methylacyl-CoA racemase are associated with prostate cancer risk. Zheng SL; Chang BL; Faith DA; Johnson JR; Isaacs SD; Hawkins GA; Turner A; Wiley KE; Bleecker ER; Walsh PC; Meyers DA; Isaacs WB; Xu J Cancer Res; 2002 Nov; 62(22):6485-8. PubMed ID: 12438241 [TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical antibody cocktail staining (p63/HMWCK/AMACR) of ductal adenocarcinoma and Gleason pattern 4 cribriform and noncribriform acinar adenocarcinomas of the prostate. Herawi M; Epstein JI Am J Surg Pathol; 2007 Jun; 31(6):889-94. PubMed ID: 17527076 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]